Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): 10.53%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-12.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-125.79%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-72.86%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-101.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-82.05%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
-77.92%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Agenus Inc.
Market Cap
$363.54M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-12.00%
3Y Avg
-125.79%
5Y Avg
-72.86%
Market Cap
$366.39M
Return on Invested Capital (ROIC)
-24.20%
TTM Avg
-33.45%
3Y Avg
-34.14%
5Y Avg
-28.75%
Market Cap
$368.91M
Return on Invested Capital (ROIC)
-1.84%
TTM Avg
-2.07%
3Y Avg
-43.39%
5Y Avg
-53.01%
Market Cap
$373.40M
Return on Invested Capital (ROIC)
-10.85%
TTM Avg
-10.82%
3Y Avg
-40.29%
5Y Avg
-33.17%
Market Cap
$348.85M
Return on Invested Capital (ROIC)
17.99%
TTM Avg
23.20%
3Y Avg
26.35%
5Y Avg
40.47%
Market Cap
$348.59M
Return on Invested Capital (ROIC)
-27.16%
TTM Avg
-54.52%
3Y Avg
-49.44%
5Y Avg
-51.83%
Market Cap
$345.48M
Return on Invested Capital (ROIC)
-40.51%
TTM Avg
-48.13%
3Y Avg
-48.38%
5Y Avg
-39.85%
Market Cap
$339.15M
Return on Invested Capital (ROIC)
-85.56%
TTM Avg
-114.55%
3Y Avg
-77.72%
5Y Avg
-63.50%
Market Cap
$330.60M
Return on Invested Capital (ROIC)
-35.92%
TTM Avg
-35.67%
3Y Avg
-36.59%
5Y Avg
-30.23%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agenus Inc. (AGEN) | $363.54M | N/A | -12.00% | -125.79% | -72.86% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $366.39M | -24.20% | -33.45% | -34.14% | -28.75% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $368.91M | -1.84% | -2.07% | -43.39% | -53.01% |
| Canopy Growth Corporation (CGC)vs › | $373.40M | -10.85% | -10.82% | -40.29% | -33.17% |
| Embecta Corp. (EMBC)vs › | $348.85M | 17.99% | 23.20% | 26.35% | 40.47% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | -27.16% | -54.52% | -49.44% | -51.83% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $345.48M | -40.51% | -48.13% | -48.38% | -39.85% |
| Cabaletta Bio, Inc. (CABA)vs › | $339.15M | -85.56% | -114.55% | -77.72% | -63.50% |
| C4 Therapeutics, Inc. (CCCC)vs › | $330.60M | -35.92% | -35.67% | -36.59% | -30.23% |
| CapsoVision, Inc. (CV)vs › | $329.01M | -164.32% | -159.25% | -125.06% | -125.06% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-03-31 | 10.53% |
| 2025-12-31 | -34.52% |
| 2024-09-30 | -65.54% |
| 2024-06-30 | -323.01% |
| 2024-03-31 | -85.63% |
| 2023-12-31 | -274.32% |
| 2023-09-30 | -154.98% |
| 2023-06-30 | -115.69% |
| 2023-03-31 | -88.94% |
| 2022-12-31 | -79.68% |
| 2022-09-30 | -65.22% |
| 2022-06-30 | 17.25% |
| 2022-03-31 | 10.83% |
| 2021-12-31 | 8.31% |
| 2021-09-30 | 20.16% |
| 2021-06-30 | -183.90% |
| 2021-03-31 | -84.42% |
| 2020-12-31 | -137.18% |
| 2020-09-30 | -195.34% |
| 2020-06-30 | -257.39% |
| 2020-03-31 | -232.03% |
| 2019-12-31 | -207.68% |
| 2019-09-30 | -162.08% |
| 2019-06-30 | -81.54% |
| 2019-03-31 | -36.29% |
| 2018-12-31 | -180.80% |
| 2018-09-30 | -157.93% |
| 2018-06-30 | -148.55% |
| 2018-03-31 | -131.24% |
| 2017-12-31 | -101.17% |
| 2017-09-30 | -81.42% |
| 2017-06-30 | -68.22% |
| 2017-03-31 | -55.53% |
| 2016-12-31 | -92.43% |
| 2016-09-30 | -75.60% |
| 2016-06-30 | -49.40% |
| 2016-03-31 | -47.56% |
| 2015-12-31 | -37.81% |
| 2015-09-30 | -37.40% |
| 2015-06-30 | -49.58% |
| 2015-03-31 | -53.59% |
| 2014-12-31 | -65.17% |
| 2014-09-30 | -40.57% |
| 2014-06-30 | -34.91% |
| 2014-03-31 | -30.81% |
| 2013-12-31 | -89.03% |
| 2013-09-30 | -73.48% |
| 2013-06-30 | -124.53% |
| 2013-03-31 | -76.18% |
| 2012-12-31 | -22.41% |
| 2012-06-30 | -25.38% |
| 2012-03-31 | -22.45% |
| 2011-12-31 | -125.15% |
| 2011-09-30 | -102.25% |
| 2011-06-30 | -111.36% |
| 2011-03-31 | -92.95% |
| 2010-12-31 | -84.85% |
| 2010-09-30 | -75.85% |
| 2010-06-30 | -62.75% |
| 2010-03-31 | -72.68% |
| 2009-12-31 | -62.48% |
| 2009-09-30 | -64.77% |
| 2009-06-30 | -98.89% |
| 2009-03-31 | -87.95% |
| 2008-12-31 | -75.55% |
| 2008-09-30 | -69.92% |
| 2008-06-30 | -58.74% |
| 2008-03-31 | -67.67% |
| 2007-12-31 | -91.67% |
| 2007-09-30 | -85.03% |
| 2007-06-30 | -81.08% |
| 2007-03-31 | -77.52% |
| 2006-12-31 | -79.06% |
| 2006-09-30 | -116.52% |
| 2006-06-30 | -111.54% |
| 2006-03-31 | -98.79% |
| 2005-12-31 | -82.93% |
| 2005-09-30 | -37.20% |
| 2005-06-30 | -59.00% |
| 2005-03-31 | -47.43% |
| 2004-12-31 | -59.26% |
| 2004-09-30 | -52.24% |
| 2004-06-30 | -46.04% |
| 2004-03-31 | -44.93% |
| 2003-12-31 | -54.80% |
| 2003-09-30 | -48.23% |
| 2003-06-30 | -55.84% |
